Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbSci ( (ABSI) ) has shared an announcement.
On July 24, 2025, Absci Corporation announced an underwritten public offering of 16,670,000 shares of its common stock at $3.00 per share, potentially raising approximately $46.7 million, or $53.7 million if additional shares are purchased. The proceeds will support the development of Absci’s internal asset programs, investment in its Integrated Drug Creation platform, and general corporate purposes, positioning the company for further growth in the biopharmaceutical industry.
The most recent analyst rating on (ABSI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on AbSci stock, see the ABSI Stock Forecast page.
Spark’s Take on ABSI Stock
According to Spark, TipRanks’ AI Analyst, ABSI is a Neutral.
AbSci’s stock score reflects a complex balance of strong technical momentum and strategic earnings call insights against significant financial challenges and valuation concerns. The company’s innovative focus and partnerships offer growth potential, but operational inefficiencies and cash flow issues pose substantial risks.
To see Spark’s full report on ABSI stock, click here.
More about AbSci
Absci is a clinical-stage biopharmaceutical company that leverages generative AI and scalable wet lab technologies to develop breakthrough therapeutics. Headquartered in Vancouver, WA, with facilities in New York City and Zug, Switzerland, Absci focuses on creating biologics more efficiently for patients.
Average Trading Volume: 3,666,427
Technical Sentiment Signal: Hold
Current Market Cap: $447.7M
See more data about ABSI stock on TipRanks’ Stock Analysis page.